Mucosal inflammation in spondylarthritides: Past, present, and future

Current Rheumatology Reports

Volumn 13, Issue 5, 2011, Pages 409-415

  Van Praet, Liesbet ^a   Van Den Bosch, Filip ^a   Mielants, Herman ^a   Elewaut, Dirk ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

Ankylosing spondylitis; Arthritis; Crohn's disease; Cytokines; Gut inflammation; HLA B27; IBD; Inflammatory bowel disease; Interleukin; Mucosal inflammation; Spondylarthritides; Sulfasalazine; Tumor necrosis factor alpha

Indexed keywords

ADALIMUMAB; AIN 457; CELECOXIB; CERTOLIZUMAB PEGOL; CYTOKINE; ETANERCEPT; ETORICOXIB; GOLIMUMAB; HLA B27 ANTIGEN; INFLIXIMAB; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR ANTIBODY; MONOCLONAL ANTIBODY; NATALIZUMAB; PLACEBO; SALAZOSULFAPYRIDINE; SECUKINUMAB; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; USTEKINUMAB; VEDOLIZUMAB;

ANKYLOSING SPONDYLITIS; ARTHRITIS; CHRONIC INFLAMMATION; CLINICAL FEATURE; CLINICAL RESEARCH; CROHN DISEASE; DISEASE ASSOCIATION; ENTERITIS; GENETICS; HUMAN; MEDICAL DECISION MAKING; MUCOSA INFLAMMATION; NONHUMAN; PATHOPHYSIOLOGY; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; REVIEW; RHEUMATOID ARTHRITIS; SPONDYLOARTHROPATHY; ULCERATIVE COLITIS;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; BIOLOGICAL MARKERS; CYTOKINES; HUMANS; INFLAMMATION; INFLAMMATORY BOWEL DISEASES; INTESTINAL MUCOSA; SPONDYLARTHRITIS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 80755153169     PISSN: 15233774     EISSN: 15346307     Source Type: Journal    
DOI: 10.1007/s11926-011-0198-2     Document Type: Review

References (65)

1. De Keyser F, Baeten D, Van den Bosch F, et al. Structuremodifying capacity of anti-tumour necrosis factor-alpha therapy in ankylosing spondylitis. Drugs. 2004, 64(24):2793-811. (Pubitemid 40007485)
2. Sieper J, Rudwaleit M, Khan MA, Braun J. Concepts and epidemiology of spondyloarthritis. Best Pract Res Clin Rheumatol. 2006, 20(3):401-17. (Pubitemid 43843063)
3. Abraham C, Cho J. Inflammatory bowel disease. N Engl J Med. 2009, 361(21):2066-78.
4. Mielants H, Veys EM, Devos M, et al. The evolution of spondyloarthropathies in relation to gut histology. I. Clinical aspects. J Rheumatol. 1995, 22(12):2266-72.
5. Mielants H, Veys EM, Cuvelier C, De Vos M, Botelberghe L. HLA-B27 related arthritis and bowel inflammation. Part 2. Ileocolonoscopy and bowel histology in patients with HLA-B27 related arthritis. J Rheumatol. 1985, 12(2):294-8. (Pubitemid 15025372)
6. Leirisalo-Repo M, Turunen U, Stenman S, Helenius P, Seppala K. High frequency of silent inflammatory bowel disease in spondylarthropathy. Arthritis Rheum. 1994, 37(1):23-31. (Pubitemid 24027690)
7. Simenon G, Van Gossum A, Adler M, Rickaert F, Appelboom T. Macroscopic and microscopic gut lesions in seronegative spondyloarthropathies. J Rheumatol. 1990, 17(11):1491-4.
8. Altomonte L, Zoli A, Veneziani A, et al. Clinically silent inflammatory gut lesions in undifferentiated spondyloarthropathies. Clin Rheumatol. 1994, 13(4):565-70. (Pubitemid 24382789)
9. Mielants H, Veys E, Cuvelier C, De Vos M. Course of gut inflammation in spondylarthropathies and therapeutic consequences. Bailliere Clin Rheumatol. 1996, 10(1):147-64. (Pubitemid 26122079)
10. Schatteman L, Mielants H, Veys EM, et al. Gut inflammation in psoriatic arthritis: a prospective ileocolonoscopic study. J Rheumatol. 1995, 22(4):680-3.
11. Mielants H, Veys EM, Cuvelier C, et al. Gut inflammation in children with late onset pauciarticular juvenile chronic arthritis and evolution to adult spondyloarthropathy-a prospective study. J Rheumatol. 1993, 20(9):1567-72. (Pubitemid 24027334)
12. Veloso FT, Carvalho J, Magro F. Immune-related systemic manifestations of inflammatory bowel disease. A prospective study of 792 patients. J Clin Gastroenterol. 1996, 23(1):29-34. (Pubitemid 26244497)
13. Orlando A. Gastrointestinal lesions associated with spondyloarthropathies. World J Gastroenterol. 2009, 15(20):2443.
14. Cuvelier C, Barbatis C, Mielants H, Devos M, Roels H, Veys E. Histopathology of intestinal inflammation related to reactive arthritis. Gut. 1987, 28(4):394-401. (Pubitemid 17056872)
15. Mielants H, Veys EM, Cuvelier C, et al. The evolution of spondyloarthropathies in relation to gut histology. III. Relation between gut and joint. J Rheumatol. 1995, 22(12):2279-84.
16. Felder JB, Korelitz BI, Rajapakse R, Schwarz S, Horatagis AP, Gleim G. Effects of nonsteroidal antiinflammatory drugs on inflammatory bowel disease: a case-control study. Am J Gastroenterol. 2000, 95(8):1949-54.
17. Mahadevan U, Loftus Jr EV, Tremaine WJ, Sandborn WJ. Safety of selective cyclooxygenase-2 inhibitors in inflammatory bowel disease. Am J Gastroenterol. 2002, 97(4):910-4. (Pubitemid 34408247)
18. Matuk R, Crawford J, Abreu MT, Targan SR, Vasiliauskas EA, Papadakis KA. The spectrum of gastrointestinal toxicity and effect on disease activity of selective cyclooxygenase-2 inhibitors in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2004, 10(4):352-6. (Pubitemid 39029177)
19. Takeuchi K, Smale S, Premchand P, et al. Prevalence and mechanism of nonsteroidal anti-inflammatory drug-induced clinical relapse in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2006, 4(2):196-202. (Pubitemid 43199690)
20. Reinisch W, Miehsler W, Dejaco C, et al. An open-label trial of the selective cyclo-oxygenase-2 inhibitor, rofecoxib, in inflammatory bowel disease-associated peripheral arthritis and arthralgia. Aliment Pharm Ther. 2003, 17(11):1371-80. (Pubitemid 36774144)
21. Biancone L, Tosti C, Geremia A, et al. Rofecoxib and early relapse of inflammatory bowel disease: an open-label trial. Aliment Pharm Ther. 2004, 19(7):755-64. (Pubitemid 38496641)
22. Sandborn WJ, Stenson WF, Brynskov J, et al. Safety of celecoxib in patients with ulcerative colitis in remission: a randomized, placebo-controlled, pilot study. Clin Gastroenterol Hepatol. 2006, 4(2):203-11 (Pubitemid 43199691)
23. El Miedany Y, Youssef S, Ahmed I, El Gaafary M. The gastrointestinal safety and effect on disease activity of etoricoxib, a selective COX-2 inhibitor in inflammatory bowel diseases. Am J Gastroenterol. 2006, 101(2):311-7. (Pubitemid 43381673)
24. Mielants H, Veys E. Ankylosing spondylitis and reactive arthritis: pathogenic aspects and therapeutic consequences. Ghent: Ghent University; 1988.
25. Dick AP, Grayson MJ, Carpenter RG, Petrie A. Controlled trial of sulphasalazine in the treatment of ulcerative colitis. Gut. 1964;5:437-42.
26. Mielants H, Schatteman G, Gyselbrecht L, Elewaut D. Influence of sulphasalazine on the evolution of gut inflammation and locomotor manifestations in the spondylarthropathies. Br J Rheumatol. 1995;34(s1):115 (abstract n220).
27. Chen J, Liu C. Sulfasalazine for ankylosing spondylitis. Cochrane Database Syst Rev. 2005(2):CD004800. doi:10.1002/14651858. CD004800.pub2
28. Dougados M, vam der Linden S, Leirisalo-Repo M, et al. Sulfasalazine in the treatment of spondylarthropathy. A randomized, multicenter, double-blind, placebo-controlled study. Arthritis Rheum. 1995, 38(5):618-27.
29. Benitez-Del-Castillo JM, Garcia-Sanchez J, Iradier T, Banares A. Sulfasalazine in the prevention of anterior uveitis associated with ankylosing spondylitis. Eye (Lond). 2000;14(Pt 3 A):340-3. (Pubitemid 30479708)
30. Schreiber S, Fedorak RN, Nielsen OH, et al. Safety and efficacy of recombinant human interleukin 10 in chronic active Crohn's disease. Crohn's Disease IL-10 Cooperative Study Group. Gastroenterology. 2000, 119(6):1461-72. (Pubitemid 32198671)
31. Fedorak RN, Gangl A, Elson CO, et al. Recombinant human interleukin 10 in the treatment of patients with mild to moderately active Crohn's disease. The Interleukin 10 Inflammatory Bowel Disease Cooperative Study Group. Gastroenterology. 2000, 119(6):1473-82. (Pubitemid 32198672)
32. Faustini F, Zoli A, Ferraccioli GF. Immunologic and genetic links between spondylarthropathies and inflammatory bowel diseases. Eur Rev Med Pharmacol Sci. 2009;13:1-9.
33. Liu ZJ, Yadav PK, Su JL, Wang JS, Fei K. Potential role of Th17 cells in the pathogenesis of inflammatory bowel disease. World J Gastroenterol. 2009, 15(46):5784-8.
34. Jandus C, Bioley G, Rivals JP, Dudler J, Speiser D, Romero P Increased numbers of circulating polyfunctional Th17 memory cells in patients with seronegative spondylarthritides. Arthritis Rheum. 2008, 58(8):2307-17.
35. Duerr RH, Taylor KD, Brant SR, et al. A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. Science. 2006, 314(5804):1461-3. (Pubitemid 44871953)
36. Rahman P, Inman RD, Gladman DD, Reeve JP, Peddle L, Maksymowych WP Association of interleukin-23 receptor variants with ankylosing spondylitis. Arthritis Rheum. 2008, 58(4):1020-5. (Pubitemid 351564003)
37. Mannon PJ, Fuss IJ, Mayer L, et al. Anti-interleukin-12 antibody for active Crohn's disease. N Engl J Med. 2004, 351(20):2069-79. (Pubitemid 39482500)
38. Shale M, Ghosh S. Beyond TNF, Th1 and Th2 in inflammatory bowel disease. Gut. 2008, 57(10):1349-51.
39. Leso V, Leggio L, Armuzzi A, Gasbarrini G, Gasbarrini A, Addolorato G Role of the tumor necrosis factor antagonists in the treatment of inflammatory bowel disease: an update. Eur J Gastroen Hepat. 2010, 22(7):779-86.
40. Kontoyiannis D, Pasparakis M, Pizarro TT, Cominelli F, Kollias G Impaired on/off regulation of TNF biosynthesis in mice lacking TNF AU-rich elements: implications for joint and gut-associated immunopathologies. Immunity. 1999, 10(3):387-98. (Pubitemid 29165293)
41. Inman RD, Davis Jr JC, van der Heijde D, et al. Efficacy and safety of golimumab in patients with ankylosing spondylitis: results of a randomized, double-blind, placebo-controlled, phase III trial. Arthritis Rheum. 2008, 58(11):3402-12.
42. Davis Jr JC, Van der Heijde D, Braun J, et al. Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial. Arthritis Rheum. 2003, 48(11):3230-6. (Pubitemid 37409337)
43. van der Heijde D, Dijkmans B, Geusens P, et al. Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT). Arthritis Rheum. 2005, 52(2):582-91. (Pubitemid 40216323)
44. van der Heijde D, Kivitz A, Schiff MH, et al. Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2006, 54(7):2136-46. (Pubitemid 44051069)
45. van der Horst-Bruinsma IE, van Denderen JC, Visman I, Suttorp-Schulten M, Dijkmans B, Nurmohamed MT Decreased recurrence rate of anterior uveitis in ankylosing spondylitis treated with adalimumab-an interim analysis [abstract 1933]. Presented at the ACR/ARHP Scientific Meeting 2010. Atlanta, GA; November 6-11, 2010.
46. Heiligenhaus A, Thurau S, Hennig M, Grajewski RS, Wildner G. Anti-inflammatory treatment of uveitis with biologicals: new treatment options that reflect pathogenetic knowledge of the disease. Graefes Arch Clin Exp Ophthalmol. 2010, 248(11):1531-51.
47. Kavanaugh A, McInnes I, Mease P, et al. Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: twenty-four-week efficacy and safety results of a randomized, placebo-controlled study Arthritis Rheum. 2009, 60(4):976-86.
48. Ortonne JP, Tassel C, Reich K. Efficacy of certolizumab pegol, a PEGylated Fab' fragment of an anti-TNF-a monoclonal antibody, in patients previously exposed to biologicals. Preliminary results of a randomised, placebo-controlled phase II clinical trial in psoriasis. Presented at the 16th Congress of the European Academy of Dermatology and Venerology, Vienna, Austria 16-20 May 2007. 2007.
49. Marzo-Ortega H, McGonagle D, O'Connor P, Emery P Efficacy of etanercept for treatment of Crohn's related spondyloarthritis but not colitis. Ann Rheum Dis. 2003, 62(1):74-6. (Pubitemid 36005801)
50. Sandborn WJ, Hanauer SB, Katz S, et al. Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial. Gastroenterology. 2001, 121(5):1088-94. (Pubitemid 33022088)
51. Breban M. Genetics of spondyloarthritis. Best Pract Res Clin Rheumatol. 2006, 20(3):593-9. (Pubitemid 43843065)
52. Brown MA. Genetics of ankylosing spondylitis. Curr Opin Rheumatol. 2010, 22(2):126-32.
53. Duerr RH, Taylor KD, Brant SR, et al. A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. Science. 2006, 314(5804):1461-3. (Pubitemid 44871953)
54. Jacques P, Elewaut D. Joint expedition: linking gut inflammation to arthritis. Mucosal Immunol. 2008, 1(5):364-71.
55. •• Danoy P, Pryce K, Hadler J, et al. Association of variants at 1q32 and STAT3 with ankylosing spondylitis suggests genetic overlap with Crohn's disease. PLoS Genetics. 2010;6(12):e1001195. This paper provides evidence for additional shared genetic associations between AS and IBD and confirms the importance of the Th17 lymphocyte subset in the pathogenesis of AS.
56. Francois RJ, Neure L, Sieper J, Braun J. Immunohistological examination of open sacroiliac biopsies of patients with ankylosing spondylitis: detection of tumour necrosis factor alpha in two patients with early disease and transforming growth factor beta in three more advanced cases. Ann Rheum Dis. 2006, 65(6):713-20. (Pubitemid 43799168)
57. Bal A, Unlu E, Bahar G, Aydog E, Eksioglu E, Yorgancioglu R. Comparison of serum IL-1 beta, sIL-2R, IL-6, and TNF-alpha levels with disease activity parameters in ankylosing spondylitis. Clin Rheumatol. 2007, 26(2):211-5. (Pubitemid 46020247)
58. Visvanathan S, Wagner C, Marini JC, et al. Inflammatory biomarkers, disease activity and spinal disease measures in patients with ankylosing spondylitis after treatment with infliximab. Ann Rheum Dis. 2008, 67(4):511-7. (Pubitemid 351498433)
59. Maini RN, Taylor PC, Szechinski J, et al. Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. Arthritis Rheum. 2006, 54(9):2817-29. (Pubitemid 44497760)
60. Ito H, Takazoe M, Fukuda Y, et al. A pilot randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohn's disease. Gastroenterology. 2004, 126(4):989-96. discussion 47. (Pubitemid 38451170)
61. Tanaka T, Kuwahara Y, Shima Y, et al. Successful treatment of reactive arthritis with a humanized anti-interleukin-6 receptor antibody, tocilizumab. Arthritis Rheum. 2009, 61(12):1762-4.
62. Brulhart L, Nissen MJ, Chevallier P, Gabay C. Tocilizumab in a patient with ankylosing spondylitis and Crohn's disease refractory to TNF antagonists. Joint, bone, spine: revue du rhumatisme 2010.
63. • Baeten D, Sieper J, Emery P, et al. The anti-IL17A monoclonal antibody secukinumab (AIN457) showed good safety and efficacy in the treatment of active ankylosing spondylitis [abstract L7]. Presented at the ACR/ARHP Scientific Meeting 2010. Atlanta, GA; November 6-11, 2010. These results, although they are interim results, suggest a major role for the Th17 pathway as a new therapeutic target for AS in the very near future.
64. MacDonald JK, McDonald JW. Natalizumab for induction of remission in Crohn's disease. Cochrane Database of Systematic Reviews. 2007(1):CD006097. doi:10.1002/14651858. CD006097. pub2
65. Elewaut D, De Keyser F, Van Den Bosch F, et al. Enrichment of T cells carrying beta7 integrins in inflamed synovial tissue from patients with early spondyloarthropathy, compared to rheumatoid arthritis. J Rheumatol. 1998, 25(10):1932-7. (Pubitemid 28459306)